Skip to main content
European Commission logo print header

Intracellular antibody Immunity

Objectif

Antibodies are a critical component of immune defence but they provide purely extracellular protection – once inside a cell, a pathogen is safe. This is the view of humoral immunity that has existed for over 100 years. However, recent work in my lab has led to the discovery of a missing system of antibody-mediated immunity that takes place inside infected cells. I have identified a novel cytosolic antibody receptor (TRIM21) that binds to antibody-coated viruses after cellular infection and targets them for degradation in the proteasome. Importantly, TRIM21-mediated immunity is capable of clearing a cell of virus within hours of infection. This discovery represents a paradigm shift in how we think about viral immunity and offers the potential for new types of antiviral drugs.

This grant application outlines key experiments to determine how intracellular antibody immunity works, what it works against and how we can augment or replicate it in the treatment of disease.

Appel à propositions

ERC-2011-StG_20101109
Voir d’autres projets de cet appel

Régime de financement

ERC-SG - ERC Starting Grant

Institution d’accueil

MEDICAL RESEARCH COUNCIL
Contribution de l’UE
€ 1 124 340,00
Adresse
20 Park Crescent
W1B 1AL LONDON
Royaume-Uni

Voir sur la carte

Type d’activité
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Contact administratif
Elizabeth Cutler (Ms.)
Chercheur principal
Leo James (Dr.)
Liens
Coût total
Aucune donnée

Bénéficiaires (1)